Login / Signup

Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.

Christopher J ScudderKatarina HazuchovaRuth GostelowDavid B ChurchYaiza ForcadaRobert C FowkesStijn Jm Niessen
Published in: Journal of feline medicine and surgery (2020)
Cabergoline did not improve diabetic control or normalise insulin-like growth factor concentration, or improve patient quality of life.
Keyphrases
  • type diabetes
  • case report
  • metabolic syndrome
  • wound healing
  • insulin resistance
  • adipose tissue
  • skeletal muscle
  • replacement therapy
  • weight loss